Canatu Oyj (HEL:CANATU)

Finland · Delayed Price · Currency is EUR

8.06

+0.36 (4.68%)

At close: Apr 27, 2026

-22.50% (1Y)

Market Cap	280.28M
Revenue (ttm)	16.70M
Net Income (ttm)	-9.70M
Shares Out	34.77M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,407
Average Volume	12,131
Open	7.71
Previous Close	7.70
Day's Range	7.71 - 8.18
52-Week Range	6.80 - 11.90
Beta	0.46
RSI	56.98
Earnings Date	Aug 25, 2026

About Canatu Oyj

Canatu Oyj develops and sells carbon nanotubes (CNTs) and related products, and manufacturing equipment for the semiconductor, automotive, and medical diagnostics industries in Finland, the United States, Japan, and Taiwan. The company offers custom CNT synthesis reactors; CNT membrane for high-power EUV lithography and X-Ray filter applications; EUV pellicies to protect photomask for contamination while permitting high EUV transmission; optical filters for use in X-Ray filter applications; and inspection membranes that enhances quality control... [Read more]

Industry Specialty Chemicals

Sector Materials

Founded 2004

Employees 181

Stock Exchange Nasdaq Helsinki

Ticker Symbol CANATU

Full Company Profile

Financial Performance

In 2025, Canatu Oyj's revenue was 16.70 million, an increase of 406.06% compared to the previous year's 3.30 million. Losses were -9.70 million, 169.4% more than in 2024.

Financial Statements

News

Canatu Oyj Transcript: CMD 2026

Transitioning from technology validation to scalable value creation, the company targets EUR 100–150 million revenue and 25–30% EBIT margin by 2030, driven by semiconductor growth and recurring revenues. High barriers to entry, disciplined capital allocation, and a flexible business model underpin expansion in automotive and medical diagnostics.

4 weeks ago - Transcripts

Canatu Oyj Earnings Call Transcript: H2 2025

Revenue declined 29% to EUR 15.6 million due to delayed reactor orders, but gross margin improved and automotive revenue more than doubled. Strong cash position enables continued investment, with key operational targets set for 2026 and new long-term guidance to be announced in March.

2 months ago - Transcripts

Canatu Oyj Earnings Call Transcript: H1 2025

H1 revenue fell 34% year-over-year to $7.3 million due to semiconductor industry delays, but gross margin improved to 67.3%. Strategic investments in new facilities, medical diagnostics, and business development continue, with long-term targets maintained despite increased timeline risk.

8 months ago - Transcripts

Canatu Oyj Earnings Call Transcript: H2 2024

Revenue grew over 60% to EUR 22 million in 2024, led by semiconductor reactor shipments and strong inspection membrane sales. Gross margin was 62.5%, with adjusted EBIT margin at -21.9%. Long-term targets remain EUR 100 million revenue and 30%+ EBIT margin by 2027.

1 year ago - Transcripts

Canatu Oyj Transcript: CMD 2024

A full share deal with Lifeline SPAC I secures up to €105 million for growth, with a €230 million valuation and new institutional investors. The company targets over €100 million revenue and >30% EBIT by 2027, driven by proprietary CNT technology in semiconductors, automotive, and diagnostics.

1 year ago - Transcripts